NUVB
Nuvation Bio Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.6% ·
share flow -2.7% ·
net new positions +5.3%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 82.70K | $409,370 | n/a | n/a |
| Q2 2026 | 95 | +2 | 157.33M | $893.25M | +5 | −5 |
| Q1 2026 | 98 | +3 | 147.71M | $634.66M | +12 | −9 |
| Q4 2025 | 94 | +2 | 141.34M | $1.26B | +2 | n/a |
| Q3 2025 | 19 | +1 | 120.52M | $443.85M | +2 | −1 |
| Q2 2025 | 15 | 0 | 120.03M | $233.06M | +1 | −1 |
| Q1 2025 | 12 | -1 | 18.55M | $32.01M | n/a | −1 |
| Q4 2024 | 13 | 0 | 18.40M | $47.86M | n/a | n/a |
| Q3 2024 | 12 | +1 | 12.76M | $28.26M | +1 | n/a |
| Q2 2024 | 11 | n/a | 9.41M | $26.24M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 50.57M | -0.9% | $187.11M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 2 | BlackRock ✦ (passive) | 24.76M | -4.4% | $91.07M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 3 | The Vanguard Group ✦ (passive) | 15.45M | -2.8% | $57.18M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | State Street Global Advisors ✦ (passive) | 6.09M | +9.5% | $22.53M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 5.89M | -1.8% | $21.79M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Millennium Management ✦ | 4.85M | -9.8% | $17.95M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 2.38M | +95.7% | $8.80M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 2.38M | -57.6% | $8.54M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 9 | AQR Capital Management ✦ | 2.03M | +78.9% | $7.53M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 10 | JPMorgan Chase ✦ | 1.35M | n/a | $5.00M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Morgan Stanley ✦ | 1.32M | n/a | $4.88M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | Goldman Sachs Group ✦ | 1.20M | n/a | $4.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Wellington Management ✦ | 868.53K | +18.4% | $3.21M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 14 | Arrowstreet Capital ✦ | 464.00K | New | $1.72M | 0.0% | New | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 284.44K | +2.6% | $1.05M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Marshall Wace ✦ | 210.00K | -75.9% | $776,996 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Greenlight Capital (DME Capital) ✦ | 135.00K | 0.0% | $149,692 | 0.0% | Held | 6 | SEC ↗ ×2 |
| 18 | Gotham Asset Management ✦ | 17.07K | New | $63,141 | 0.0% | New | 1 | SEC ↗ |
| 19 | Adage Capital Partners ✦ | 266.67K | 0.0% | $53,893 | 0.0% | Held | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $1.72M | 0.0% |
| Gotham Asset Management | $63,141 | 0.0% |
Exited
| Renaissance Technologies | $43,095 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 230 holders, 219.97M shares, $906.24M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 100.00K sh · $709,240
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology